HIV-1 CNS in vitro infectivity models based on clinical CSF samples

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 1, 2016, Pages 235-243

  Mora Peris, Borja ^a,b   Winston, Alan ^a,b   Garvey, Lucy ^a,b   Else, Laura ^c   Shattock, Robin ^a   Herrera, Carolina ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; LOPINAVIR; MARAVIROC; NEVIRAPINE; RILPIVIRINE; RITONAVIR; TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; ASTROCYTE; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CEREBROSPINAL FLUID LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC50; IN VITRO STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS REPLICATION; CELL CULTURE; CELL CULTURE TECHNIQUE; CEREBROSPINAL FLUID; CHEMISTRY; DRUG EFFECTS; DRUG MONITORING; GLIA; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; VIROLOGY; VIRUS CULTURE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASTROCYTES; CELL CULTURE TECHNIQUES; CELLS, CULTURED; CEREBROSPINAL FLUID; DRUG MONITORING; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEUROGLIA; VIRUS CULTIVATION;

EID: 84960099523     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv326     Document Type: Article

References (47)

1. Everall I, Vaida F, Khanlou N et al. Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. J Neurovirol 2009; 15: 360-70.
2. Lescure FX, Omland LH, Engsig FN et al. Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study. Clin Infect Dis 2011; 52: 235-43.
3. Heaton RK, Clifford DB, Franklin DR Jr et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010; 75: 2087-96.
4. Cysique LA, Brew BJ. Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression. J Neurovirol 2011; 17: 176-83.
5. Heaton RK, Franklin DR, Ellis RJ et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011; 17: 3-16.
6. Hinkin CH, Castellon SA, Durvasula RS et al. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology 2002; 59: 1944-50.
7. Brew BJ. Benefit or toxicity from neurologically targeted antiretroviral therapy? Clin Infect Dis 2010; 50: 930-2.
8. Benedict RH, Mezhir JJ, Walsh K et al. Impact of human immunodeficiency virus type-1-associated cognitive dysfunction on activities of daily living and quality of life. Arch Clin Neuropsychol 2000; 15: 535-44.
9. Ellis RJ, Hsia K, Spector SA et al. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol 1997; 42: 679-88.
10. Ellis RJ, Moore DJ, Childers ME et al. Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol 2002; 59: 923-8.
11. Calcagno A, Di Perri G, Bonora S. Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system. Clin Pharmacokinet 2014; 53: 891-906.
12. Hunt PW, Martin JN, Sinclair E et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187: 1534-43.
13. Ellis RJ, Badiee J, Vaida F et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 2011; 25: 1747-51.
14. Marra CM, Zhao Y, Clifford DB et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009; 23: 1359-66.
15. Robertson KR, Su Z, Margolis DM et al. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology 2010; 74: 1260-6.
16. Enting RH, Hoetelmans RM, Lange JM et al. Antiretroviral drugs and the central nervous system. AIDS 1998; 12: 1941-55.
17. Cysique LA, Vaida F, Letendre S et al. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 2009; 73: 342-8.
18. d'Arminio Monforte A, Cinque P, Mocroft A et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 2004; 55: 320-8.
19. Yilmaz A, Verhofstede C, D'Avolio A et al. Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy. J Acquir Immune Defic Syndr 2010; 55: 590-6.
20. Letendre S, Marquie-Beck J, Capparelli E et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65: 65-70.
21. Tozzi V, Balestra P, Salvatori MF et al. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr 2009; 52: 56-63.
22. Smurzynski M, Wu K, Letendre S, Robertson K et al. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 2011; 25: 357-65.
23. Shikuma CM, Nakamoto B, Shiramizu B et al. Antiretroviral monocyteefficacy score linked to cognitive impairment in HIV. Antivir Ther 2012; 17: 1233-42.
24. Edén A, Price RW, Spudich S et al. Immune activation of the central nervous system is still present after .4 years of effective highly active antiretroviral therapy. J Infect Dis 2007; 196: 1779-83.
25. Harezlak J, Buchthal S, Taylor M et al. Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS 2011; 25: 625-33.
26. Lee PL, Yiannoutsos CT, Ernst Tet al. A multi-center 1H MRS study of the AIDS dementia complex: validation and preliminary analysis. J Magn Reson Imaging 2003; 17: 625-33.
27. Winston A, Duncombe C, Li PC et al. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis 2010; 50: 920-9.
28. Garvey L, Nelson M, Latch N et al. CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study. J Antimicrob Chemother 2012; 67: 206-12.
29. Mora-Peris B,Watson V, Vera JH et al. Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy. J Antimicrob Chemother 2014; 69:1642-740.
30. Vodicka MA, Goh WC, Wu LI et al. Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses. Virology 1997; 233: 193-8.
31. Björndal A, Deng H, Jansson M et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 1997; 71: 7478-87.
32. Li Y, Hui H, Burgess CJ et al. Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: evidence for limited defectiveness and complementation. J Virol 1992; 66: 6587-600.
33. Li Y, Kappes JC, Conway JA et al. Molecular characterization of human mmunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes. J Virol 1991; 65: 3973-85.
34. Guha D, Nagilla P, Redinger C et al. Neuronal apoptosis by HIV-1 Vpr: contribution of proinflammatory molecular networks frominfected target cells. J Neuroinflammation 2012; 9: 138.
35. Biswas P, Tambussi G, Lazzarin A. Access denied? The status of co-receptor inhibition to counter HIV entry. Expert Opin Pharmacother 2007; 8: 923-33.
36. Stephenson J. Researchers buoyed by novel HIV drugs: will expand drug arsenal against resistant virus. JAMA 2007; 297: 1535-6.
37. Emmelkamp JM, Rockstroh JK. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions-review of the literature. Eur J Med Res 2007; 12: 409-17.
38. Wilson M, Reynolds G, Kauppinen RA et al. A constrained least-squares approach to the automated quantitation of in vivo 1H magnetic resonance spectroscopy data. Magn Reson Med 2011; 65: 1-12.
39. Herrera C, Shattock RJ. Candidate microbicides and their mechanisms of action. Curr Top Microbiol Immunol 2014; 383: 1-25.
40. Van Noort JM. Human glial cell culture models of inflammation in the central nervous system. Drug Discov Today 2006; 11: 74-80.
41. McMahon MA, Shen L, Siliciano RF. New approaches for quantitating the inhibition of HIV-1 replication by antiviral drugs in vitro and in vivo. Curr Opin Infect Dis 2009; 22: 574-82.
42. Wang J, Gabuzda D. Reconstitution of human immunodeficiency virus-induced neurodegeneration using isolated populations of human neurons, astrocytes, and microglia and neuroprotection mediated by insulin-like growth factors. J Neurovirol 2006; 12: 472-91.
43. Wang T, Gong N, Liu J et al. HIV-1-infected astrocytes and the microglial proteome. J Neuroimmune Pharmacol 2008; 3: 173-86.
44. Writing GroupWilliams I, Churchill D, Anderson J et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013). HIV Med 2014; 15 Suppl 1: 1-85.
45. Asboe D, Williams IG, Goodall RL et al. A virological benefit from an induction/maintenance strategy: the Forte trial. Antivir Ther 2007; 12: 47-54.
46. Best BM, Letendre SL, Brigid E et al. Low atazanavir concentrations in cerebrospinal fluid. AIDS 2009; 23: 83-7.
47. Sailasuta N, Ross W, Ananworanich J et al. Change in brain magnetic resonance spectroscopy after treatment during acute HIV infection. PLoS One 2012; 7: e492.